Fiche publication
Date publication
mai 2024
Journal
Expert opinion on drug metabolism & toxicology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Faggiani I, D'Amico F, Bernardi F, Bencardino S, Allocca M, Furfaro F, Parigi TL, Zilli A, Fiorno G, Peyrin-Biroulet L, Danese S
Lien Pubmed
Résumé
Janus kinases (JAK) are enzymes involved in signaling pathways that activate the immune system. Upadacitinib, an oral small molecule, is the first JAK inhibitor approved by FDA and EMA for the treatment of moderately to severely active Crohn's disease (CD), following successful phase II and III trials. Compared to other JAK inhibitors, upadacitinib has a high selectivity toward JAK1. This characteristic could improve its efficacy and safety.
Mots clés
Crohn’s disease, Upadacitinib, pharmacokinetics, targeted small molecules
Référence
Expert Opin Drug Metab Toxicol. 2024 05 7;:
